Second-line treatment of advanced colorectal cancer with a biweekly oxaliplatin plus irinotecan combination regimen

Onkologie

Volumn 25, Issue 4, 2002, Pages 358-362

  Schull B ^a   Kornek, G V ^a   Schmid, K ^a   Raderer, M ^a   Ulrich Pur, H ^a   Fiebiger, W ^a   Schneeweiss, B ^b   Lenauer, A ^c   Depisch, D ^a   Scheithauer, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Kirchdorf General Hospital   (Switzerland)

^c Wr Neustadt General Hospital   (Austria)

Author keywords

Advanced colorectal cancer; Irinotecan; Oxaliplatin; Second line treatment

Indexed keywords

DEXAMETHASONE; IRINOTECAN; ONDANSETRON; OXALIPLATIN; RALTITREXED;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; QUINAZOLINES; THIOPHENES; TREATMENT FAILURE;

EID: 18544374574     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066054     Document Type: Article

References (20)

1. Schmoll HJ, Büchele T, Schöber C: The role of second-line chemotherapy in colorectal cancer. Onkologie 1997;20:288-294.
2. Henderson CA: Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure. Semin Oncol 1998;25(suppl 11):29-38.
3. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
4. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
5. Witkovic E, Bekradda M: Oxaliplatin: A new therapeutic option in colorectal cancer. Semin Oncol 1999;26:647-662.
6. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-98.
7. Brienza S, Bensmaine MA, Soulie P, Louvet C, Gamelin E, Francois E, Ducreux M, Marty M, Andre T, de Braud F, Bleiberg H, Segal V, Itzhaki M, Cvitkovic E: Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/-FA) in the treatment of 5-FU pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program. Ann Oncol 1999;10:1311-1316.
8. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Gilles V, Lotz JP, Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Ann Oncol 2000;11:1477-1483.
9. Culy CR, Clemett D, Wiseman LR: Oxaliplatin. A review of its pharmacological properties and clinic efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000;60:895-924.
10. Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F: Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diamino-cyclohexane platinum derivate oxaliplatin. Clin Cancer Res 1999;5:1189-1196.
11. Erlichman C, Boerner S, Kaufmann SH: Mechanisms of synergy between oxaliplatin and the topoisomerase I inhibitor SN-38. Clin Cancer Res 1999;5:3853(abstract).
12. Wasserman E, Cuvier C, Lokiec F, Goldwasser F, Kalla S, Mery-Mignard D, Ouldkaci M, Besmaine A, Dupont-Andre G, Mahjoubi M, Marty M, Misset JL, Cvitkovic E: Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999;17:1751-1759.
13. Goldwasser F, Gross-Goupil M, Tigaud JM, Di Palma M, Marceau-Suissa J, Wasserman E, Yovine A, Misset JL, Cvitkovic E: Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients. Ann Oncol 2000;11:1463-1470.
14. Scheithauer W, Kornek GV, Raderer M, Valencak J, Weinländer G, Hejna M, Haider K, Kwasny W, Depisch D: Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol 1999;17:902-906.
15. Kemeny N, Tong W, Stockman J, Blanchette J, Saltz L: Phase I trial of weekly oxaliplatin and irinotecan in previously treated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000;19:245a (abstract 984).
16. Becouarn Y, Gamelin E, Coudert B, Negrier S, Pierga JY, Raoul JL, Provencal J, Rixe O, Krisch C, Germa C, Bekradda M, Mignard D, Mousseau M: Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan with oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001;19:4195-4202.
17. Scheithauer W, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Gedlicka C, Schüll B, Brugger S, Schneeweiss B, Lang F, Lenauer A, Depisch D: Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol 2002;20 (in press).
18. MacDonald J, Haller D, Mayer R: Grading of toxicity; in MacDonald J, Haller D, Mayer R (eds): Manual of Oncologic Therapeutics. Philadelphia PA, Lippincott, 1995, pp 519-523.
19. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
20. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.